A randomized, double-blind, placebo-controlled proof-of-concept parallel group clinical trial to investigate the efficacy, safety and tolerability of weekly subcutaneous (SC) dosing of CK-0045 in participants with overweight / obesity and Type 2 diabetes

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514191-41-00

Acronym

CK-0045_CS02

Enrollment

Registered

2024-09-10

Start date

2024-09-16

Completion date

2025-10-21

Last updated

2025-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes and Obesity

Brief summary

Change from baseline in area under the plasma glucose (PG) curve after a MMTT (AUCPG0- 4h) after 16 weeks of treatment.

Detailed description

Change from baseline in body weight, total cholesterol, HDL-, LDL-cholesterol, triglycerides, free fatty acids (FFA), Lp(a), and HbA1c after 16 weeks of treatment.

Interventions

DRUGnon-preserved sterile liquid formulation

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in area under the plasma glucose (PG) curve after a MMTT (AUCPG0- 4h) after 16 weeks of treatment.	—

Secondary

Measure	Time frame
Change from baseline in body weight, total cholesterol, HDL-, LDL-cholesterol, triglycerides, free fatty acids (FFA), Lp(a), and HbA1c after 16 weeks of treatment.	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026